Compound laminine-amlodipine anti-hypertension preparation

A technology of laminin and compound preparations, which is applied in the field of medicine, can solve the problems of increasing the incidence of adverse reactions, complex pathogenesis of hypertension, and low effective rate, and achieve the effect of reducing the dosage, reducing the dosage, and reducing the dosage

Inactive Publication Date: 2014-06-18
QINGDAO UNIV OF SCI & TECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The pathogenesis of hypertension is complex, and the effective rate of single drug treatment is relatively low. Although increasing the dose c

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound laminine-amlodipine anti-hypertension preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0033] Example 2 Antihypertensive Effect Experiment 2 on Spontaneously Hypertensive Rats

[0034] In this example ， The amount of laminin or pharmaceutically acceptable salt of laminin used is 30 mg to 70 mg per unit dose, calculated as laminin, and the drugs used are respectively laminin besylate; amlodipine or ammonium chloride The dosage of the pharmaceutically acceptable salt of dipine is 1 mg to 1.5 mg per unit dose, calculated as amlodipine; the amlodipine used is amlodipine maleate. The dosages mentioned are all based on human dosage.

[0035] The experimental scheme, experimental animals, and experimental process are all the same as in Example 1, and the obtained experimental results are also the same as in Example 1, and will not be repeated here.

Embodiment

[0036] Example 3 Antihypertensive Effect Experiment 3 on Spontaneously Hypertensive Rats

[0037] In this example ， The amount of laminin or a pharmaceutically acceptable salt of laminin used is 30 mg to 70 mg per unit dose, calculated as laminin, and the drugs used are laminin maleate; amlodipine or ammonium chloride The dosage of the pharmaceutically acceptable salt of dipine is 1 mg to 1.5 mg per unit dose, calculated as amlodipine. The amlodipine used is amlodipine besylate. The dosages mentioned are all based on human dosage.

[0038] The experimental scheme, experimental animals, and experimental process are all the same as in Example 1, and the obtained experimental results are also the same as in Example 1, and will not be repeated here.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a compound laminine-amlodipine anti-hypertension preparation for treating hypertension. The compound laminine-amlodipine anti-hypertension preparation is prepared by combining an active ingredient formed by laminine or pharmaceutically acceptable salts thereof and amlodipine or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable adjunct according to a certain ratio. An animal experiment shows that the laminine has good synergistic effect with the amlodipine or an amlodipine combination, and the compound preparation is more remarkable in the antihypertensive efficacy compared with the preparation with independent use of the laminine. The compound laminine-amlodipine anti-hypertension preparation has the advantages that the formula is reasonable, the drug dosage is reduced, and the antihypertensive efficacy is strengthened.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a compound prepared from laminin or a pharmaceutically acceptable salt of laminin, amlodipine or a pharmaceutically acceptable salt of amlodipine and pharmaceutically acceptable auxiliary materials Laminbutin amlodipine antihypertensive preparation. Background technique [0002] Hypertension is one of the most common cardiovascular diseases in the world today and the leading cause of death and disability in adults. At the same time, it is also the most important factor leading to coronary heart disease, stroke, congestive heart failure and renal dysfunction, and its morbidity and mortality have surpassed tumor diseases and ranked first. Recent studies have shown that the incidence rate of hypertension among people over 15 years old is 18.8%, and the number of hypertensive patients in my country reaches 160 million, and it increases at a rate of more than 300 million people every year. my...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4422A61P9/12A61K31/205
Inventor 张媛媛刘均洪宿烽
Owner QINGDAO UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap